Corbus Other Operating Expenses from 2010 to 2025
| CRBP Stock | USD 8.51 0.97 10.23% |
Other Operating Expenses | First Reported 2013-03-31 | Previous Quarter 11 M | Current Value 15.5 M | Quarterly Volatility 10.1 M |
Check Corbus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Corbus Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 651.3 K, Interest Expense of 3.5 M or Selling General Administrative of 13.9 M, as well as many indicators such as Price To Sales Ratio of 93.82, Dividend Yield of 0.0 or Days Sales Outstanding of 191. Corbus financial statements analysis is a perfect complement when working with Corbus Pharmaceuticals Valuation or Volatility modules.
Corbus | Other Operating Expenses |
Latest Corbus Pharmaceuticals' Other Operating Expenses Growth Pattern
Below is the plot of the Other Operating Expenses of Corbus Pharmaceuticals Holding over the last few years. Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Corbus Pharmaceuticals. It is also known as Corbus Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. It is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. Corbus Pharmaceuticals' Other Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Corbus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Other Operating Expenses | 10 Years Trend |
|
Other Operating Expenses |
| Timeline |
Corbus Other Operating Expenses Regression Statistics
| Arithmetic Mean | 38,266,332 | |
| Geometric Mean | 12,565,815 | |
| Coefficient Of Variation | 101.89 | |
| Mean Deviation | 29,785,462 | |
| Median | 35,003,011 | |
| Standard Deviation | 38,989,179 | |
| Sample Variance | 1520.2T | |
| Range | 126.2M | |
| R-Value | 0.63 | |
| Mean Square Error | 990.9T | |
| R-Squared | 0.39 | |
| Significance | 0.01 | |
| Slope | 5,124,812 | |
| Total Sum of Squares | 22802.3T |
Corbus Other Operating Expenses History
About Corbus Pharmaceuticals Financial Statements
Corbus Pharmaceuticals shareholders use historical fundamental indicators, such as Other Operating Expenses, to determine how well the company is positioned to perform in the future. Although Corbus Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Corbus Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Corbus Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Other Operating Expenses | 51.8 M | 50.8 M |
Additional Tools for Corbus Stock Analysis
When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.